| Surefire Resources NL (SRN) ORDINARY FULLY PAID |
Materials |
$4 |
VMS Style Recognised at Copper Hill
|
26 Feb 2025 10:19AM |
$0.004 |
$0.002 |
fallen by
62.50%
|
|
SRN - Price-sensitive ASX Announcement
Full Release
Key Points
- VMS style recognized at the Copper Hill Project from petrographic study
- Widespread sulphidic veins of VMS style occur in a tholeiitic basalt submarine volcanic system setting
- Petrographical work has identified potential VMS affinities
- NITON pXRF analyses show typical assemblage for VMS style mineralization
- Significant copper mineralization recognized within a broad sulphidic zone
- Further targeted exploration planned for massive sulphides within the VMS system
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Reinstatement to Official Quotation
|
26 Feb 2025 10:16AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Suspension of trading in ALA securities will be lifted.
- Reinstatement occurs after announcement about capital raising.
- Signifies return to normal operations after suspension.
- Reflects confidence in Arovella's financial activities.
- Indicates future plans for the company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Proposed issue of securities - ALA
|
26 Feb 2025 10:16AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Proposed issue of securities - ALA
|
26 Feb 2025 10:16AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Cancel - Proposed issue of securities - ALA
|
26 Feb 2025 10:16AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Prospectus
|
26 Feb 2025 10:15AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Arovella is offering 100 new shares at $0.125 each.
- The offer includes 39,905,699 placement options.
- The funds raised will support the ALA-101 clinical trial.
- Arovella’s products face significant regulatory hurdles.
- Investment in Arovella is considered highly speculative.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hejaz Sukuk Active ETF (Managed Fund) (SKUK) |
Financials |
$7 |
Quarterly Portfolio Disclosure - December 2024
|
26 Feb 2025 10:15AM |
$1.070 |
$1.100 |
risen by
2.80%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$97 |
Arovella $15m Placement to fund Phase 1
|
26 Feb 2025 10:15AM |
$0.195 |
$0.082 |
fallen by
57.95%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Arovella received firm commitments for a new placement of approximately $15 million.
- The capital raised allows completion of enrollment for ALA-101 Phase 1 clinical trial.
- Funds will support development of Arovella's solid tumor programs.
- The previous placement announced on 10 January 2025 was withdrawn due to a private investor default.
- Arovella plans to report initial safety and efficacy data from the Phase 1 trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Timah Resources Limited (TML) ORDINARY FULLY PAID |
Utilities |
$3 |
Change in Registered Office and Principal Place of Business
|
26 Feb 2025 10:14AM |
$0.041 |
$0.035 |
fallen by
14.63%
|
|
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$91 |
1H FY25 Market Update
|
26 Feb 2025 10:14AM |
$0.500 |
$0.400 |
fallen by
20%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Genetic Signatures Limited provided a market update for 1H FY25.
- The company is focusing on expanding its market presence.
- There are targeted market segments identified for growth.
- The potential market size for testing services is substantial.
- Innovation in genetic testing is a key strategy for the company.
- The update highlights operational enhancements to capture market share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$91 |
Positive Momentum For The First Half Result
|
26 Feb 2025 10:13AM |
$0.500 |
$0.400 |
fallen by
20%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- 136% improvement in sales during 1H FY25 to $8.5 million
- Gross margin increased to 59% in 1H FY25
- 20% improvement in underlying loss for 1H FY25 to $8.4 million
- Statutory loss of $15.2 million recorded for 1H FY25
- Cash and cash equivalents stood at $40.8 million as of 31 December 2024
- Completion of strategic assessment for automated technology solutions
- Secured first US commercial contract in February 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$91 |
Half Yearly Report and Accounts
|
26 Feb 2025 10:12AM |
$0.500 |
$0.400 |
fallen by
20%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales increased to $8.5 million from $3.6 million in the prior half-year.
- Loss of $15.2 million recorded, including $6.8 million in impairment expenses.
- Strategic decision made to cease internal development of the Next Generation Instrument.
- Gross margin improved to 59% due to decreased inventory obsolescence.
- Challenges faced in US product launch due to customer procurement processes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$88 |
Japan Patent Allowance for RECCE Anti-Infectives
|
26 Feb 2025 10:12AM |
$0.445 |
$0.305 |
fallen by
31.46%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Japan Patent Office has allowed a new patent for RECCE anti-infectives.
- Patent Family 4 includes RECCE® 327 and RECCE® 529.
- Patent covers process preparation, use for treating various infections.
- Japan represents the third-largest pharmaceutical market globally.
- Antibiotic resistance market in Japan projected to reach $411.3 million by 2030.
- Recce's anti-infectives aim to address urgent global health problems.
- Global patent protection underscores commitment to innovative therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance ZincTek Limited (ANO) ORDINARY FULLY PAID |
Materials |
$49 |
Application for quotation of securities - ANO
|
26 Feb 2025 10:06AM |
$0.785 |
$0.780 |
fallen by
0.64%
|
|
| Respiri Limited (RSH) ORDINARY FULLY PAID |
Health Care |
- |
Initial Director's Interest Notice
|
26 Feb 2025 10:05AM |
$0.051 |
$0.033 |
fallen by
35.29%
|
|
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$4,194 |
Change of Director's Interest Notice - Lynne Saint
|
26 Feb 2025 10:04AM |
$4.250 |
$5.000 |
risen by
17.65%
|
|
| Respiri Limited (RSH) ORDINARY FULLY PAID |
Health Care |
- |
Final Director's Interest Notice
|
26 Feb 2025 10:04AM |
$0.051 |
$0.033 |
fallen by
35.29%
|
|
| Meridian Energy Limited (MEZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$13,600 |
Dividend/Distribution - MEZ
|
26 Feb 2025 10:04AM |
$5.110 |
$5.200 |
risen by
1.76%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$701 |
Appendix 4G and Corporate Governance Statement
|
26 Feb 2025 10:02AM |
$3.580 |
$2.070 |
fallen by
42.18%
|
|
| Janus Henderson Sustainable Credit Active ETF (Managed Fund) (GOOD) |
Financials |
$2 |
GOOD - February 2025 Distribution Estimate CPU
|
26 Feb 2025 10:02AM |
$50.660 |
$51.190 |
risen by
1.05%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,710 |
FDA accepts BLA and grants priority review for Zircaix
|
26 Feb 2025 9:58AM |
$31.140 |
$25.750 |
fallen by
17.31%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA accepted BLA for TLX250-CDx (Zircaix) for kidney cancer imaging.
- TLX250-CDx aims to diagnose and characterize clear cell renal cell carcinoma.
- BLA based on successful Phase 3 ZIRCON study with high sensitivity and specificity.
- FDA granted Priority Review with a PDUFA date of August 27, 2025.
- Potential commercial launch in the U.S. in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Blackstone Minerals Limited (BSX) ORDINARY FULLY PAID |
Materials |
$63 |
Placement of Shortfall and Cleansing Notice
|
26 Feb 2025 9:57AM |
$0.050 |
$0.092 |
risen by
84%
|
|
BSX - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed placement of Shortfall Shares raising $2.25 million
- A total of 74,946,591 shares placed at $0.03 each
- 600,000 shares issued upon exercising unlisted options
- Cleansing Notice issued under section 708A(5)(e) of the Corporations Act
- Compliance with provisions of Chapter 2M and sections 674 and 674A confirmed
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Farm Pride Foods Limited (FRM) ORDINARY FULLY PAID |
Consumer Staple |
$67 |
Section 708A Cleansing Notice
|
26 Feb 2025 9:56AM |
$0.180 |
$0.290 |
risen by
61.11%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$701 |
2024 Full Year Results Presentation
|
26 Feb 2025 9:56AM |
$3.580 |
$2.070 |
fallen by
42.18%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 151% on prior corresponding period to $281 million.
- Strong performance fees of $84.5 million.
- Net inflows of $1.9 billion, up 310% on prior corresponding period.
- Funds under management grew by 64% to $18.0 billion.
- Normalized NPAT of $97.5 million, up 198% on prior year.
- 2H24 dividend of 10 cents per share, 100% franked.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vonex Limited. (VN8) ORDINARY FULLY PAID |
Communication Services |
$19 |
Application for quotation of securities - VN8
|
26 Feb 2025 9:56AM |
$0.036 |
$0.025 |
fallen by
30.56%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
